The introduction of the National Health (Privacy) Rules 2025 marks a significant shift in the privacy settings governing the handling of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) claims information by Australian Government agencies. Taking effect on April 1, 2025,
In a groundbreaking initiative aimed at transforming the health regulatory landscape across the African continent, the first African Regulators Leadership Program (ARLP) was convened at the Wits Business School in Johannesburg. This program is designed to elevate the leadership skills and
The hospice industry faces significant regulatory challenges that have become more pronounced in recent years, with key concerns including evolving telehealth policies and program integrity issues. These challenges were highlighted by hospice professionals in the 2025 Outlook Survey conducted by
Ivan Kairatov is a Biopharma expert with extensive knowledge in technology and innovation within the industry and considerable experience in research and development. Today, we discuss the newly introduced Genomic Data Protection Act (GDPA) and its implications. Can you explain the main purpose of
Clinical trials have long been criticized for their lack of diversity, particularly in the participation of women. Historically, such exclusions have led to significant gaps in medical knowledge and treatment efficacy across genders, resulting in potentially biased outcomes for a substantial
In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin
